富士莱：截至目前，公司已收到江苏省药品监督管理局的药品GMP符合性检查结果告知书

Core Viewpoint - Fujifilm announced on November 25 that it has received the GMP compliance inspection result notification from the Jiangsu Provincial Drug Administration, confirming that its active pharmaceutical ingredient, Apatinib Mesylate, meets GMP standards, laying a solid foundation for future commercialization [1] Group 1 - The company has successfully passed the GMP compliance inspection for its raw material drug Apatinib Mesylate [1] - This compliance is crucial for the subsequent commercialization of the product [1]